Abstract: An improved method of treatment with cabazitaxel composition that is substantially free of premedication prior to the administration of the cabazitaxel composition to the patient.

Abstract: The present invention provides a stable, non-aqueous, ready-to-use parenteral composition comprising: carfilzomib or pharmaceutically acceptable salt thereof, acidifying agent, optionally a surfactant, one or more solvents or co-solvents.

Abstract: The present invention provides a stable, non-aqueous, ready-to-use parenteral composition comprising: carfilzomib or pharmaceutically acceptable salt thereof, acidifying agent, optionally a surfactant, one or more solvents or co-solvents.

Abstract: The present invention relates to a stable non-aqueous, ready to dilute liquid pharmaceutical composition comprising (i) melphalan or a pharmaceutically acceptable salt thereof and (ii) polyoxyethylene sorbitan fatty acid esters; wherein the weight ratio of melphalan to polyoxyethylene sorbitan fatty acid esters is from about 1:0.75 to about 1:20; wherein, composition comprising melphalan, at a concentration of about 50 mg/ml to about 150 mg/ml; wherein, when the composition is diluted to produce melphalan at a concentration of about 0.1 to about 3 mg/ml, is physically and chemically stable up to about 4 hours.

Abstract: The present invention provides a stable, non-aqueous, ready-to-use parenteral composition comprising: carfilzomib or pharmaceutically acceptable salt thereof, acidifying agent, optionally a surfactant, one or more solvents or co-solvents.

Abstract: The invention provides a process for preparing a sterile suspension comprising aripiprazole. More particularly, the invention provides the process for preparing the sterile suspension comprising aripiprazole, wherein said process involves in-process moist-heat sterilization of said suspension comprising aripiprazole. The in-process moist-heat sterilization is particularly efficient and economical process for the sterilization of aripiprazole formulations for parenteral administration, wherein the formulation obtained by said process have comparable physicochemical characteristics with the commercially available Ability Maintena® Injection.